| Differential prognostic impact of comorbidity | Journal of Clinical Oncology | 2004 | 265 |
| ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia | Blood | 2005 | 205 |
| Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells | Journal of Clinical Investigation | 1998 | 192 |
| Acquired CD40-ligand deficiency in chronic lymphocytic leukemia | Nature Medicine | 1997 | 171 |
| A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia | Leukemia and Lymphoma | 2015 | 125 |
| Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics | International Journal of Cancer | 2006 | 105 |
| BCR-ABL-transformed GMP as myeloid leukemic stem cells | Proceedings of the National Academy of Sciences of the United States of America | 2008 | 76 |
| Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis | Proceedings of the National Academy of Sciences of the United States of America | 2017 | 75 |
| Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI | Lung Cancer | 2015 | 63 |
| Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy | Nature Communications | 2020 | 62 |
| Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers | Cancer Research | 2017 | 61 |
| Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Journal of the National Cancer Institute | 2019 | 50 |
| Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians | Journal of Emergency Medicine | 2018 | 45 |
| Monoclonal antibodies in the treatment of cancer | Critical Reviews in Oncology/Hematology | 1984 | 39 |
| Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department | Annals of Emergency Medicine | 2017 | 35 |
| Integrin αvβ5 Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy | Cell Reports | 2020 | 32 |
| Bortezomib is effective in primary plasma cell leukemia | Leukemia and Lymphoma | 2006 | 30 |
| Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis | Cellular Immunology | 1999 | 30 |
| Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL | PLoS ONE | 2011 | 29 |
| Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A | Gene Therapy | 2000 | 27 |
| CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes | Blood | 2000 | 26 |
| APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy | OncoImmunology | 2019 | 26 |
| Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells | Experimental Hematology | 2007 | 25 |
| Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy | International Journal of Hematology | 2008 | 24 |
| Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity | Cell Death and Differentiation | 2013 | 23 |
